The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Diabetes, Metabolic Syndrome and Obesity · 2024-02 · Volume 17 · 701-714
DOI: 10.2147/dmso.s443396 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2024-02. Verfasst von Xiaoyu Lv und 8 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To explore the effects of Tirzepatide (TZP), a new hypoglycemic drug, on weight, blood lipids and blood pressure in overweight/obese patients with type 2 diabetes mellitus (T2DM).
Methods
Relevant studies investigating the influence of TZP therapy on weight, lipid profiles and blood pressure in overweight/obese T2DM patients were selected from the PubMed, Embase, Web of Science and Cochrane databases from establishment until November 2022. A systematic review and meta-analysis were conducted to evaluate the effect of TZP on weight, blood lipids and blood pressure in overweight/obese patients with T2DM.
Results
Eight randomized controlled trials (RCTs), comprising 7491 patients with T2DM, were included in the meta-analysis. Results showed that compared with the glucagon-like peptide-1 receptor agonist (GLP-1RA), insulin, and placebo groups, body weight, triglycerides (TG), very low-density lipoprotein cholesterol (VLDL-C), total cholesterol (TC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c) levels were significantly decreased in the TZP-treated groups, while high-density lipoprotein cholesterol (HDL-C) levels increased. With the gradual increase of TZP doses, the proportions of T2DM patients with weight loss >5% gradually increased. The 10 mg and 15 mg TZP doses had a stronger effect on the levels of TG, VLDL-C, and HDL-C. Moreover, the reduction in SBP levels in the 15 mg TZP-treated group was more pronounced than those in the 10 mg and 5 mg TZP-treated groups [MD=-2.07, 95% CI (-2.52, -1.63) and MD=-3.14, 95% CI (-4.42, -1.87)]. Compared with GLP-1RA, insulin, and placebo groups, the proportions of patients with HbA1c
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
- Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China.
ORCID-Profile: Xiaoyu Lv, Hui Wang, Jingfang Liu
Zitieren
APA
Lv, X., Wang, H., Chen, C., Zhao, Y., Li, K., Wang, Y., Wang, L., Fu, S., & Liu, J. (2024). The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes, Metabolic Syndrome and Obesity, Volume 17, 701-714. https://doi.org/10.2147/dmso.s443396
Vancouver
Lv X, Wang H, Chen C, Zhao Y, Li K, Wang Y, et al. The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes, Metabolic Syndrome and Obesity. 2024;Volume 17:701-714. doi:10.2147/dmso.s443396
BibTeX
@article{Lv2024,
author = {Lv, Xiaoyu and Wang, Hui and Chen, Chongyang and Zhao, Yangting and Li, Kai and Wang, Yawen and Wang, Liting and Fu, Songbo and Liu, Jingfang},
title = {The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2024},
volume = {Volume 17},
pages = {701--714},
doi = {10.2147/dmso.s443396}
}
EUVIMED